Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy

Clinical Immunology

Volumn 127, Issue 3, 2008, Pages 394-400

  Virella, Gabriel ^a   Carter, Rickey E ^b   Saad, Antonio ^a,c   Crosswell, Edward G ^a,c   Game, B Andrew ^a,c   Lopes Virella, Maria F ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Diabetes; Immune complexes; Nephropathy; Oxidized LDL antibodies

Indexed keywords

ALBUMIN; CREATININE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; EXCRETION; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MIDDLE AGED; PILOT PROJECTS;

EID: 45249087013     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.02.005     Document Type: Article

References (54)

1. Steinbrecher U.P., Fisher M., Witztum J.L., and Curtiss L.K. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 25 (1984) 1109-1116
2. Virella G., Thorpe S., Alderson N.L., Derrick M.B., Chassereau C., Rhett J.M., and Lopes-Virella M.F. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Res. 45 (2004) 1859-1867
3. Palinski W., Yla-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., and Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10 (1990) 325-335
4. Steinbrecher U.P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262 (1987) 3603-3608
5. Yla-Herttuala S., Palinski W., Butler S., Picard S., Steinberg D., and Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14 (1994) 32-40
6. Mironova M., Virella G., and Lopes-Virella M.F. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 222-229
7. Virella G., Koskinen S., Krings G., Onorato J.M., Thorpe S.R., and Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 95 (2000) 135-144
8. Virella G., and Lopes-Virella M.F. Lipoprotein autoantibodies: measurement and significance. Clin. Diagn. Lab. Immunol. 10 (2003) 499-505
9. Virella G., Atchley D.H., Koskinen S., Zheng D., and Lopes-Virella M. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 105 (2002) 81-92
10. Saad A.F., Virella G., Chassereau C., Boackle R.J., and Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 47 (2006) 1975-1983 (Electronic publication 2006 Jun 1927)
11. Virella G. Biosynthesis, metabolism and biological properties of immunoglobulins. Medical Immunology. 6th ed. (2007), Informa, N.Y. and London 65-72
12. Virella G., and Tsokos G. Immune complex diseases. In: Virella G. (Ed). Medical Immunology (2007), Informa, N.Y. and London 453?-471?
13. Bellomo G., Maggi E., Poli M., Agosta F.G., Bollati P., and Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 44 (1995) 60-66
14. Erkkilä A.T., Närvänen O., Lehto S., Uusitupa M.I.J., and Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 204-209
15. Lehtimaki T., Lehtinen S., Solakivi T., Nikkila M., Jaakkola O., Jokela H., Yla-Herttuala S., Luoma J.S., Koivula T., and Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 23-27
16. Maggi E., Chiesa R., Melissano G., Castellano R., Astore D., Grossi A., Finardi G., and Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14 (1994) 1892-1899
17. Palinski W., Yla-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., and Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10 (1990) 325-335
18. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., and Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
19. Takeuchi M., Makita Z., Yanagisawa K., Kameda Y., and Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5 (1999) 393-405
20. Boullier A., Hamon M., Walters-Laporte E., Martin-Nizart F., Mackereel R., Fruchart J.C., Bertrand M., and Duriez P. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin. Chim. Acta 238 (1995) 1-10
21. Festa A., Kopp H.P., Schernthaner G., and Menzel E.J. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41 (1998) 350-356
22. Hulthe J., Wiklund O., Hurt-Camejo E., and Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler. Thromb. Vasc. Biol. 21 (2001) 269-274
23. Hulthe J., Bokemark L., and Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 101-107
24. Virella G., Virella I., Leman R.B., Pryor M.B., and Lopes-Virella M.F. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23 (1993) 95-101
25. van de Vijver L.P., Steyger R., van Poppel G., Boer J.M., Kruijssen D.A., Seidell J.C., and Princen H.M. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122 (1996) 245-253
26. Wu R., de Faire U., Lemne C., Witztum J.L., and Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33 (1999) 53-59
27. Leinonen J.S., Rantalaiho V., Laippala P., Wirta O., Pasternack A., Alho H., Jaakkola O., Yla-Herttuala S., Koivula T., and Lehtimaki T. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus. Free Radic. Res. 29 (1998) 137-141
28. Uusitupa M.I.J., Niskanen L., Luoma J., Vilja P., Rauramaa R., and Ylä-Herttula S. Autoantibodies against oxidized LDL do not predict atherosclerosis vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1236-1242
29. Orchard T.J., Virella G., Forrest K.Y., Evans R.W., Becker D.J., and Lopes-Virella M.F. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48 (1999) 1454-1458
30. Lopes-Virella M.F., Virella G., Orchard T.J., Koskinen S., Evans R.W., Becker D.J., and Forrest K.Y. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin. Immunol. 90 (1999) 165-172
31. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., and Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84 (1989) 1086-1095
32. Griffith R.L., Virella G.T., Stevenson H.C., and Lopes-Virella M.F. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J. Exp. Med. 168 (1988) 1041-1059
33. Orekhov A.N., Kalenich O.S., Tertov V.V., and N.I.D. Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue. React. 13 (1991) 233-236
34. Lopes-Virella M.F., McHenry M.B., Lipsitz S., Yim E., Wilson P.F., Lackland D.T., Lyons T., Jenkins A.J., and Virella G. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 190 (2007) 359-369
35. Atchley D.H., Lopes-Virella M.F., Zheng D., and Virella G. Oxidized LDL-Anti-Oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45 (2002) 1562-1571
36. Yishak A.A., Costacou T., Virella G., Zgibor J., Fried L., Walsh M., Evans R.W., Lopes-Virella M., Kagan V.E., Otvos J., and Orchard T.J. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol. Dial. Transplant. 21 (2006) 93-100 (Electronic publication 2005 Sep 2006)
37. Binder C.J., Chang M.K., Shaw P.X., Miller Y.E., Hartvigsen K., Dewan A., and W.J.L. Innate and acquired immunity in atherogenesis. Nat. Med. 8 (2002) 1218-1226
38. Yamashita T., Freigang S., Eberle C., Pattison J., Gupta S., Napoli C., and Palinski W. Maternal immunization programs postnatal immune responses and reduces atherosclerosis in offspring. Circ. Res. 99 (2006) e51-e64
39. Karvonen J., Paivansalo M., Kesaniemi Y.A., and Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108 (2003) 2107-2112 (Electronic publication 2003 Oct 2106)
40. Tsimikas S., Witztum J.L., Miller E.R., Sasiela W.J., Szarek M., Olsson A.G., and Schwartz G.G. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412 (Electronic publication 2004 Sep 1407)
41. Fredrikson G.N., Hedblad B., Berglund G., Alm R., Nilsson J.A., Schiopu A., Shah P.K., and Nilsson J. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38 (2007) 1495-1500
42. Lopes-Virella M.F., Koskinen S., Mironova M., Horne D., Klein R., Chasssereau C., Enockson C., and Virella G. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis 152 (2000) 105-113
43. Virella G., Thorpe S.R., Alderson N.L., Stephan E.M., Atchley D.H., Wagner F., Lopes-Virella M.F., and Group D.E.R. Autoimmune response to advanced glycosylation end-products of human low density lipoprotein. J. Lipid Res. 443 (2003) 487-493
44. Schoenfeld D. Statistical considerations for pilot studies. Int. J. Radiat. Oncol. Biol. Phys. 6 (1980) 371-374
45. Cosio F.G., Giebink G.S., Le C.T., and Schiffman G. Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients. Kidney Int. 20 (1981) 254-258
46. Girndt M. Humoral immune responses in uremia and the role of IL-10. Blood Purif. 20 (2002) 485-488
47. Kamata K., and Okubo M. Derangement of humoral immune system in nondialyzed uremic patients. Jpn. J. Med. 23 (1984) 9-15
48. Virella G. Humoral immune response and its induction by active immunization. In: Virella G. (Ed). Medical Immunology. 6th ed. (2007), Informa, N.Y. and London 159-172
49. Binder C.J., Horkko S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., Shaw P.X., Palinski W., Witztum J.L., and Silverman G.J. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9 (2003) 736-743 (Electronic publication 2003 May 2012)
50. Damoiseaux J., Rijkers G., and Tervaert J.W. Pneumococcal vaccination does not increase circulating levels of IgM antibodies to oxidized LDL in humans and therefore precludes an anti-atherogenic effect. Atherosclerosis 190 (2007) 10-11
51. Mironova M., Virella G., Virella-Lowell I., and Lopes-Virella M.F. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85 (1997) 73-82
52. Orekhov A.N., Kalenich O.S., Tertov V.V., and Novikov I.D. Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13 (1991) 233-236
53. Virella G., Wohltmann H., Sagel J., Lopes-Virella M.F., Kilpatrick J.M., Phillips C., and Colwell J. Soluble immune complexes in patients with diabetes mellitus: detection and pathological significance. Diabetologia 21 (1981) 189-191
54. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130 (1999) 461-470